
Sign up to save your podcasts
Or


Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors. They address funding, the partnering market, AI, and also the recent FDA and CGT roundtable discussion.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Peter Ronco, CEO, Emmes
Phil Vanek, Founder, Redline Bio Advisors; Chief Commercial Officer, ISCT; Entrepreneur in Residence, Georgetown University School of Medicine
Richard Daly, President & Chief Executive Officer, Catalyst Pharmaceuticals
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
By BioSpace4.9
1313 ratings
Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors. They address funding, the partnering market, AI, and also the recent FDA and CGT roundtable discussion.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Peter Ronco, CEO, Emmes
Phil Vanek, Founder, Redline Bio Advisors; Chief Commercial Officer, ISCT; Entrepreneur in Residence, Georgetown University School of Medicine
Richard Daly, President & Chief Executive Officer, Catalyst Pharmaceuticals
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

91,163 Listeners

30,707 Listeners

43,586 Listeners

8,789 Listeners

972 Listeners

4,397 Listeners

1,171 Listeners

1,975 Listeners

56,928 Listeners

9,563 Listeners

338 Listeners

6,125 Listeners

6,582 Listeners

35 Listeners

21 Listeners